Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1999 1
2000 1
2007 1
2012 3
2013 3
2014 3
2015 12
2016 14
2017 19
2018 33
2019 39
2020 62
2021 72
2022 80
2023 98
2024 97
2025 128
2026 67

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

676 results

Results by year

Filters applied: . Clear all
Page 1
Circulating tumor DNA and liquid biopsy in oncology.
Cescon DW, Bratman SV, Chan SM, Siu LL. Cescon DW, et al. Nat Cancer. 2020 Mar;1(3):276-290. doi: 10.1038/s43018-020-0043-5. Epub 2020 Mar 20. Nat Cancer. 2020. PMID: 35122035 Review.
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the capabilities of this technology as a diagnostic test. The full potential of ctDNA …
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor cancer have matured rapidly. An inc …
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Moding EJ, et al. Cancer Discov. 2021 Dec 1;11(12):2968-2986. doi: 10.1158/2159-8290.CD-21-0634. Cancer Discov. 2021. PMID: 34785539 Free PMC article. Review.
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse. ...Here, we review the evidence supporting the value of ctDNA MRD in solid cancers and …
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for sol …
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
Widman AJ, Shah M, Frydendahl A, Halmos D, Khamnei CC, Øgaard N, Rajagopalan S, Arora A, Deshpande A, Hooper WF, Quentin J, Bass J, Zhang M, Langanay T, Andersen L, Steinsnyder Z, Liao W, Rasmussen MH, Henriksen TV, Jensen SØ, Nors J, Therkildsen C, Sotelo J, Brand R, Schiffman JS, Shah RH, Cheng AP, Maher C, Spain L, Krause K, Frederick DT, den Brok W, Lohrisch C, Shenkier T, Simmons C, Villa D, Mungall AJ, Moore R, Zaikova E, Cerda V, Kong E, Lai D, Malbari MS, Marton M, Manaa D, Winterkorn L, Gelmon K, Callahan MK, Boland G, Potenski C, Wolchok JD, Saxena A, Turajlic S, Imielinski M, Berger MF, Aparicio S, Altorki NK, Postow MA, Robine N, Andersen CL, Landau DA. Widman AJ, et al. Nat Med. 2024 Jun;30(6):1655-1666. doi: 10.1038/s41591-024-03040-4. Epub 2024 Jun 14. Nat Med. 2024. PMID: 38877116 Free PMC article.
In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response monitoring. To overcome the sparsity of ctDNA fragments in low tumor …
In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment o …
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.
Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G. Valenza C, et al. Ann Oncol. 2025 Jul;36(7):726-736. doi: 10.1016/j.annonc.2025.03.019. Epub 2025 Apr 3. Ann Oncol. 2025. PMID: 40187491 Free article.
This systematic review and meta-analysis aims to assess the role of ctDNA clearance as a predictor of pCR in patients with solid tumors treated with neoadjuvant ICIs. MATERIALS AND METHODS: A systematic search of PubMed, EMBASE and conference proceedings up t …
This systematic review and meta-analysis aims to assess the role of ctDNA clearance as a predictor of pCR in patients with solid …
Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.
Pomerantz T, Brooks R. Pomerantz T, et al. Curr Treat Options Oncol. 2024 Apr;25(4):510-522. doi: 10.1007/s11864-024-01180-w. Epub 2024 Mar 12. Curr Treat Options Oncol. 2024. PMID: 38472567 Review.
Circulating tumor DNA (ctDNA) refers to small fragments of DNA released into the bloodstream by cancer cells. ...However, the use of ctDNA in diagnosis and treatment of gynecologic malignancies is currently limited, compared to adoption in other solid- …
Circulating tumor DNA (ctDNA) refers to small fragments of DNA released into the bloodstream by cancer cells. ...However, the …
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Merker JD, et al. J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5. J Clin Oncol. 2018. PMID: 29504847 Review.
Methods An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including pre-analytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. ...Evidence shows discordance between …
Methods An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including pre-analyt …
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. Pascual J, et al. Ann Oncol. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. Epub 2022 Jul 6. Ann Oncol. 2022. PMID: 35809752 Free article.
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. ...Reflex tumour testing should be considered following a non-informative ctDNA result, due to false-negative resul …
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients wi …
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Aleshin A, Torti D, Marsh K, Eagles J, Cirlan I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL, Pugh TJ. Bratman SV, et al. Nat Cancer. 2020 Sep;1(9):873-881. doi: 10.1038/s43018-020-0096-5. Epub 2020 Aug 3. Nat Cancer. 2020. PMID: 35121950
Limited data exist to show how serial circulating tumor DNA (ctDNA) testing may perform as a predictive biomarker in patients receiving ICB. We conducted a prospective phase II clinical trial to assess ctDNA in five distinct cohorts of patients with advanced …
Limited data exist to show how serial circulating tumor DNA (ctDNA) testing may perform as a predictive biomarker in patients …
An ultrasensitive method for detection of cell-free RNA.
Nesselbush MC, Luca BA, Jeon YJ, Jabara I, Meador CB, Garofalo A, Binkley MS, Hui AB, van 't Erve I, Xu N, Shi WY, Liu KJ, Sugio T, Kastelowitz N, Hamilton EG, Liu CL, Olsen M, Bonilla RF, Wang YP, Jiang A, Lau B, Eichholz J, Banwait M, Schroers-Martin J, Boegeholz J, King DA, Luikart H, Esfahani MS, Mehrmohamadi M, Stehr H, Raclin T, Tibshirani R, Khush K, Srinivas S, Yu H, Rogers AJ, Nair VS, Isbell JM, Li BT, Piotrowska Z, Sequist LV, Hata AN, Neal JW, Wakelee HA, Gentles AJ, Alizadeh AA, Diehn M. Nesselbush MC, et al. Nature. 2025 May;641(8063):759-768. doi: 10.1038/s41586-025-08834-1. Epub 2025 Apr 16. Nature. 2025. PMID: 40240612 Free PMC article.
In analytical validations, we find RARE-seq to be approximately 50-fold more sensitive for detecting tumour-derived cfRNA than whole-transcriptome RNA sequencing (RNA-seq), with a limit of detection of 0.05%. ...Detection of non-small-cell lung cancer expression signatures …
In analytical validations, we find RARE-seq to be approximately 50-fold more sensitive for detecting tumour-derived cfRNA than whole- …
Integrating liquid biopsies into the management of cancer.
Siravegna G, Marsoni S, Siena S, Bardelli A. Siravegna G, et al. Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2. Nat Rev Clin Oncol. 2017. PMID: 28252003 Review.
At present, the molecular landscapes of solid tumours are established using surgical or biopsy tissue samples. Tissue-based tumour profiles are, however, subject to sampling bias, provide only a snapshot of tumour heterogeneity, and cannot be obtained …
At present, the molecular landscapes of solid tumours are established using surgical or biopsy tissue samples. Tissue-based …
676 results